Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy
Summary
- Biohit announced that a clinical study in India found that proton pump inhibitors (PPIs) do not affect the GastroPanel Quick Test's ability to detect atrophic gastritis, supporting its clinical acceptability.
- The study, published in Anticancer Research, showed that while PPIs altered biomarker concentrations, they did not reduce the test's diagnostic accuracy, addressing concerns about its clinical utility.
- Biohit's strategic growth relies on the success of GastroPanel Quick Tests, and the study provides independent evidence to support wider adoption in healthcare protocols and screening programs.
- While individual studies may not immediately impact revenue, they are crucial for achieving Biohit's targeted annual growth of 15–20% by strengthening sales and marketing efforts.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 8/19/2026 at 7:00 am EEST.
Biohit announced on Tuesday the results of a new clinical study conducted in India that found commonly used proton pump inhibitors (PPIs) do not reduce the GastroPanel Quick Test's ability to detect atrophic gastritis. This news reinforces the company’s sales arguments and the product’s clinical acceptability, as the widespread use of PPIs could impede the test's broader adoption in primary healthcare.
Study dispels clinical uncertainty
According to a study published in the Anticancer Research journal, regular use of PPIs did not reduce the diagnostic accuracy of the GastroPanel Quick Test in identifying atrophic gastritis although, as expected, the medication affected the concentrations of individual biomarkers. Of the 266 patients enrolled in the study, more than 70% were regular users of PPI medication. Because proton pump inhibitors are very widely used to treat various stomach symptoms, we believe that their potential to interfere with test results has been a significant concern regarding the test’s clinical utility. The independent research evidence now available dispels this uncertainty and may lower the threshold for adopting the test.
Support for the commercialization of quick tests
We have previously emphasized that Biohit’s long-term strategic growth hinges greatly on the success of the GastroPanel Quick Tests (venous blood and fingertip blood tests) in both new and existing markets. For quick tests to be adopted more widely as part of healthcare treatment protocols and potential screening programs, the company needs strong, independent clinical evidence supporting the test’s reliability across various patient groups. The newly published study complements previous evidence and provides the company's distributor network with tools to support sales and marketing. Although individual studies do not directly translate into revenue in the short term, we estimate that they are important building blocks for achieving the company's targeted annual growth of 15–20%.